Get the Stockscreener App
1,068.13
0.51%
-6.5488
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,068.13, with a volume of 944.67K.
It is down -0.51% in the last 24 hours and up +2.21% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,074.68
Open:
$1076.4
24h Volume:
944.67K
Relative Volume:
0.26
Market Cap:
$956.25B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.83
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-0.79%
1M Performance:
+2.21%
6M Performance:
+37.21%
1Y Performance:
+37.42%
1-Day Range:
$1,052.08
$1,076.74
1-Week Range:
$1,052.08
$1,085.50
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,068.41 | 961.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.71 | 498.60B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.51 | 403.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
137.63 | 264.54B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
105.72 | 261.26B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Institutional Investors Signal Confidence in Eli Lilly Amidst Market Crosscurrents - AD HOC NEWS
What Makes Eli Lilly And Co. (LLY) a Worthy Holding? - Yahoo Finance
RVW Wealth LLC Invests $910,000 in Eli Lilly and Company $LLY - MarketBeat
Miracle Mile Advisors LLC Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat
Celltrion completes acquisition of US Eli Lilly plant - theinvestor.co.kr
Burns J W & Co. Inc. NY Has $3.35 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Celltrion Acquires Eli Lilly’s U.S. Facility with 680 billion won CMO Contract - Businesskorea
The Truth About Eli Lilly and Company: Why Everyone Is Betting Big On This Pharma Giant - AD HOC NEWS
Celltrion completes acquisition of Eli Lilly manufacturing facility in New Jersey - koreabiomed.com
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites - ts2.tech
Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus - ts2.tech
Smith Salley Wealth Management Has $14.84 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stake Decreased by Calamos Advisors LLC - MarketBeat
Ayrshire Capital Management LLC Has $7.42 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Strategic Gamble: Deep Price Cuts in China Challenge Profit Outlook - AD HOC NEWS
FDA Approves Novo Nordisk’s Wegovy Pill: A Game Changer for 2026 - Investing.com
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026 - ts2.tech
Could This Potential Move Boost Eli Lilly's Prospects? - AOL.com
Triangle biotech backed by Eli Lilly files to go public - The Business Journals
Segment Wealth Management LLC Buys 10,042 Shares of Eli Lilly and Company $LLY - MarketBeat
Simplify Asset Management Inc. Sells 4,453 Shares of Eli Lilly and Company $LLY - MarketBeat
Mirova US LLC Has $290.45 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Strategic Pivot: A Price War in China for Market Dominance - AD HOC NEWS
Eli Lilly Engages in Strategic Price Competition Amid Record Valuation - AD HOC NEWS
Eli Lilly-backed Insilico eyes beyond pharma with new AI models - Nikkei Asia
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight? - Benzinga
AI Company Raises 2.3 Billion Yuan for Listing with Eli Lilly and Temasek's Backing - 36Kr
The Truth About Eli Lilly and Company: Why Everyone on Wall Street Is Obsessed Right Now - AD HOC NEWS
Eli Lilly (LLY) Moves Fast to Secure Lead in India's Obesity Drug Market - Finviz
Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market - Yahoo Finance
Novo and Lilly cut prices of weight-loss drugs in China - Reuters
Lilly Endowment Sells 3,593 Shares of Eli Lilly & Co - TradingView — Track All Markets
Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China - GuruFocus
Eli Lilly’s Strategic Price Cut Intensifies Rivalry in Chinese Weight-Loss Market - AD HOC NEWS
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China - Yahoo Finance UK
Eli Lilly & Co.: How a 150-Year-Old Giant Became the Hottest Product Story in Pharma - AD HOC NEWS
Eli Lilly (LLY) and Novo Nordisk (NVO) Slash GLP-1 Drug Prices i - GuruFocus
Eli Lilly, Novo waging price wars as obesity drug market heats up in China - Seeking Alpha
Price war in China weight loss market: Novo Nordisk, Eli Lilly slash prices of Wegovy, Mounjaro - Medical Dialogues
Total Wealth Planning LLC Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Sapient Capital LLC Purchases 259,392 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly stock: juggernaut at all?time highs tests how much optimism is too much - AD HOC NEWS
Eli Lilly And Co (LLY) Stock Price Today - CoinMarketCap
Novo Nordisk, Eli Lilly cut obesity drug prices in China By Investing.com - Investing.com Australia
Novo Nordisk, Eli Lilly cut obesity drug prices in China - Investing.com
Novo Nordisk, Eli Lilly Reportedly Cut Prices of Weight Loss Drugs in CN Mkt - AASTOCKS.com
As global obesity treatments such as Eli Lilly's "Munzaro" and Novo Nordisk's "Wigobi" have gained w.. - 매일경제
Eli Lilly’s Strategic Position Holds Firm Amid Novo Nordisk’s Oral Weight-Loss Drug Approval - AD HOC NEWS
Major Eli Lilly Insider Quietly Unloads More Shares in Multi-Million Dollar Move - TipRanks
With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market - statnews.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):